Since the introduction of CT colonography (CTC) in the mid-1990s, there have been continuous advancements in the examination technique and advanced visualization software for interpretation. This review will cover the origins of CTC as a natural extension of abdominal CT imaging, and discuss the evolution of CTC through the subsequent clinical phases of feasibility, validation, and implementation.
The origins of CTC Although Coin was issued a U.S. patent for CT virtual colonoscopy in 1994 [1] , Vining and Gelfand were the first to demonstrate a 3D endoluminal fly-through of the colon using CT (i.e., ''virtual colonoscopy'') that same year [2] . However, a part of the basic technical groundwork for CTC was actually laid down much earlier [3] . By the late 1980s, it was becoming apparent that CT might be useful not only for follow-up of patients with surgically proven colorectal carcinoma (CRC), but also for preoperative assessment of CRC and perhaps even for patients with only suspected tumors [3, 4] . The potential advantages for a cross-sectional imaging technique such as CT over the barium enema may now seem obvious in retrospect, but this was still the prehelical CT era, where conventional ''step-and-shoot'' studies took a considerable amount of time and typically generated 10-mm-thick sections. In 1988, Balthazar et al. reported on the utility of a conventional CT technique that presaged subsequent CTC evaluation years later, including the use of both colonic air distention (pneumocolon) and positive oral contrast opacification [3] . In fact, that author group showed that the sensitivity for detecting CRC was 95% with the use of gaseous distention vs. 68% with conventional CT technique. This 95% sensitivity for CRC detection using colonic distention was similar to that reported in a meta-analysis for CTC nearly two decades later [5] . Interestingly, the barium enema actually outperformed CT for detecting CRC in this 1988 paper, reflecting both the fluoroscopic expertise and nascent CT technology of the time.
In an early CTC editorial by Vining in 1996 [6] , he foresaw many of the potential hurdles and controversies soon to face this promising new examination. Included in his discussion were the topics of 2D vs. 3D evaluation, colonic distention, oral contrast tagging, flat lesions, coding and reimbursement issues, standardized reporting, and appropriate clinical indications. All of these were later to become core issues, many of which remain relevant today. By 1997, several early clinical CTC series were published, including seminal work at the Mayo Clinic [7, 8] . The term ''CT colography'' was applied in some early works, but soon gave way to the more familiar terms of CT colonography and virtual colonoscopy, both of which remain in wide use today.
The introduction of spiral or helical CT in the early 1990s allowed for more rapid image acquisition and volumetric data. This advancement rendered the detection of colorectal polyps a feasible task beyond invasive CRC masses. Multidetector CT (MDCT) soon allowed for even greater coverage and thinner sections within a single breath hold, which further improved polyp detection capability at CTC [9] . Given the relatively forgiving task of unenhanced imaging of static gas-filled colon, the introduction of four detector-row scanners made it possible for CTC imaging protocols that remain diagnostically adequate to this day [10, 11] . At this point, MDCT scanner capability was no longer a major focus for continued CTC improvements, although some incremental gains were seen for 16 detector-row scanners and beyond. However, further evolution of MDCT reconstruction algorithms has since allowed for substantial dose-reduction capabilities.
MDCT advances aside, the next challenge for performing time-efficient 3D endoluminal VC was the processing speed and capability of the available computer software programs. For the first 3D endoluminal VC flythrough, more than 8 h of processing time was required to generate the images [12] . Although rapid improvements in computer processing performance soon followed, the initial concept of ''virtual colonoscopy'' as a simulated virtual-reality colonoscopic examination gave way to a primary 2D evaluation, which is more properly termed CTC over VC given the lack of virtual flythrough. As such, most CTC software platforms were initially based on a primary 2D paradigm, with 3D largely reserved for ''problem solving.'' It would be a number of years before primary 3D evaluation would become a mainstream approach. Even Vining himself seemed resigned to a 2D approach, stating in a 2005 publication that ''most practitioners of VC today agree that 2D review of CT images at a workstation is sufficient for lesion detection and that 3D imaging can be reserved for problem solving'' [12] . This 2D sentiment was also evident in a survey of 25 leading CTC experts, which was published in AJR in 2005 [13] , where only one respondent felt that primary 3D review was necessary.
The clinical evolution of CTC
Once the basic tenets of CTC were established, the next logical step was clinical evaluation of this new diagnostic tool. The clinical evolution of CTC can be considered in three sequential phases: a ''feasibility phase'' where early testing in high-prevalence cohorts provided the necessary proof of concept, a ''validation phase'' where testing in low-prevalence cohorts sought to prove its value for screening, and an ''implementation phase'' where proven techniques were applied in the clinical realm beyond the artificial clinical trial setting. In terms of clinical performance evaluation, one fact that has repeatedly (and unavoidably) plagued CTC assessment is that optical colonoscopy (OC) represents a fallible reference standard [14] . Even when the onerous step of segmental unblinding of CTC findings at OC is instituted, problems with lesion matching persist. Most notably, OC false negatives maybe incorrectly registered as CTC false positives. In addition, inaccurate sizing and localization of lesions at OC can lead to further mismatches with CTC. Further, bias and uncertainty can be introduced if the endoscopist is either not blinded to the CTC results or if the CTC results are not revealed at all. Therefore, it is useful to remember that clinical trials using an OC reference standard will generally underestimate CTC accuracy.
The feasibility phase
Beyond the earliest clinical reports on CTC performance noted above, a number of single-center CTC trials were published between 1999 and mid-2003 that ranged in size from about 50-300 patients [9, [15] [16] [17] [18] [19] [20] [21] [22] [23] . Common themes among these studies were that polyp-rich high-risk and/ or symptomatic cohorts were evaluated, single-detector MDCT scanners were generally employed, oral contrast tagging was rarely applied, a primary 2D polyp search was utilized, and segmental unblinding of CTC findings at OC was generally not employed. Nonetheless, these early clinical trials provided the necessary proof of concept that CTC was a feasible technique and could detect large colorectal polyps ( ‡ 10 mm) with reasonably good sensitivity (70-100%) and specificity (90-100%). Noteworthy, high-profile publications among this group include a study involving 100 subjects by Fenlon et al. in The New England Journal of Medicine published in 1999 and a study involving 300 subjects by Yee et al. in Radiology published in 2001 [15, 20] . Also during this time period, several clinical studies demonstrated the utility of CTC following incomplete OC [24] [25] [26] [27] . These publications were important as failed colonoscopy became the first widely accepted clinical indication for diagnostic CTC. CTC for the purpose of CRC screening, however, had yet to be validated.
The validation phase
With the feasibility trials in high-prevalence cohorts demonstrating the necessary proof of concept to move forward, the next step was to assess the performance characteristics of CTC in a low-prevalence setting. Although CTC serves a useful role for a variety of diagnostic indications, the ''holy grail'' for clinical CTC is asymptomatic screening. However, because of the lower prevalence of significant polyps among screening cohorts, larger study populations are required (e.g., > 500 subjects). The initial CTC studies involving larger cohorts did not truly assess asymptomatic average-risk adults, but did involve relatively low-prevalence cohorts.
The first large low-prevalence CTC study was published in 2003 by Johnson et al. from the Mayo Clinic, evaluating a high-risk cohort of 703 adults [28] . Like the feasibility studies before it, this single-center trial used primary 2D for polyp detection, and did not employ either oral contrast tagging or segmental unblinding. Perhaps the main reason this high-risk cohort turned out to have a low prevalence of disease (5% of subjects had large polyps) was that three-fourths of patients were undergoing post-polypectomy surveillance. Presumably, this would concentrate polyps that were missed at initial OC, or were partially resected and re-grew, either of which would likely be harder to detect compared with first-time screening [29] . In addition, the use of a relatively low-volume cutoff of carbon dioxide for initial scanning, without active replacement, may have led to suboptimal distention in some cases. These factors may account for the lower pooled sensitivity for large polyps of around 50%, although specificity was generally greater than 95%.
The next two large CTC trials evaluating low-prevalence cohorts were multicenter efforts led by two gastroenterologists, Drs. Cotton and Rockey, involving 600 and 614 subjects, respectively [30, 31] . Neither of these trials evaluated a true screening cohort, and both used a primary 2D polyp search without oral contrast tagging. Additional issues that likely had a negative impact on CTC performance in these trials included use of suboptimal CTC software, low numbers of cases per participating center, and lack of performance feedback for learning. It is important to clarify that although the studies by Cotton [11, 30, 31] . The performances in these two CTC trials were overall disappointing, with a low by-patient sensitivity for large polyps of 55-59% despite a by-patient specificity of 96%.
The DoD trial was a multicenter screening trial of 1233 subjects conducted at U.S. Navy and Army hospitals from 2001 to 2003 and published in late 2003 [11] . Key methodological differences of this trial from prior studies was the use of a CTC software system that allowed for primary 3D polyp detection, the use of oral contrast tagging, segmental unblinding of CTC results at OC, and a cohort of asymptomatic average-risk adults [32, 33] . Main results included a 94% by-patient sensitivity for large adenomas, with a specificity of 96% [11] .
Through the use of segmental unblinding, the OC miss rate for large adenomas was shown to be higher than that for CTC. At the 6-mm threshold, the by-patient CTC sensitivity for adenomas was 89%, but specificity dropped to 80%. Subsequent technical advances since the DoD trial have improved CTC performance down to the 6-mm threshold. Overall, these results led to the first FDA approval of a CTC software system for the purpose of screening. A later study showed that the polyp sensitivity for primary 2D sensitivity by trained experts reading the naval subset of CTC cases from the DoD trial closely resembled the low 2D polyp detection performance from the Cotton and Rockey trials [34] .
The ACRIN trial was a large multicenter trial involving 2531 screening subjects from a mix of 15 academic and community clinical sites, which was published in 2008 [35] . Importantly, the robust results of 90% bypatient sensitivity for large adenomas and cancers provided the final clinical validation needed for screening CTC as a generalizable technique. In addition, it found that there was no difference in performance using either primary 2D or primary 3D imaging techniques, nor were there significance differences between CTC vendor specific software platforms. Reader training and testing (which had not been performed in the Cotton and Rockey trials) was shown to be an important component for ensuring high performance interpretations [36] . Additional studies have provided even further validation for CTC. In one study by Graser et al. in 307 averagerisk adults [37] , CTC showed high sensitivity (97%) for detecting advanced neoplasia when using a primary 3D search in addition to 2D detection, compared with low detection sensitivity for FIT (32%) and FOBT (20%). Although not a screening trial, the SIGGAR study was a large randomized, controlled trial conducted in the UK. The trial consisted of two separate arms of symptomatic patients, one comparing CTC against OC [38] , and the other comparing CTC against the barium enema (BE) [39] . Collectively, these comparisons showed that CTC was equivalent to OC and superior to BE for detecting large polyps and cancers in patients with symptoms concerning for possible CRC.
The implementation phase
The next logical step beyond validation of screening CTC was actual clinical implementation. In 2008, the American Cancer Society (ACS) revised its guidelines for CRC screening, in conjunction with the three major U.S. GI societies and the American College of Radiology (ACR) [10] . These guidelines were the first to delineate the preferred preventive tests that detect relevant polyps over the stool-based cancer detection tests. Importantly, CTC was included for the first time as a recommended preventive screening test, along with endoscopy. However, despite the strong endorsement by the ACS, clinical implemen-tation of screening CTC at the national level was further delayed by the lack of support by the United States Preventive Services Task Force (USPSTF) and by the lack of coverage by CMS for Medicare beneficiaries.
Without broad implementation of CTC for screening, early clinical progress in the U.S. was largely limited to isolated centers of excellence, where local coverage was somehow secured. The two largest CTC screening programs in this early implementation phase were centered at the University of Wisconsin and the National Naval Medical Center (NNMC Bethesda, now the Walter Reed National Military Medical Center). In April 2004, the CTC program at the University of Wisconsin (UW) embarked upon the first locally reimbursed screening program. Shortly thereafter, the CTC program at NNMC began their relatively large-volume screening program within the military health system. Over the next decade or so, each program screened over 10,000 patients, with good clinical results [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] . In one CTC publication involving more than 10,000 screening adults, the overall detection rate of unsuspected cancer was approximately one CRC every 500 patients and one extracolonic cancer every 300 patients, underscoring the capability of CTC to detect important disease beyond the colon [50] . Elsewhere, more diffuse implementation of diagnostic CTC, predominately for incomplete OC, was occurring simultaneously throughout the world. A meta-analysis confirmed the high sensitivity of CTC for detecting cancer, regardless of specific technique [51] .
Early clinical implementation of screening CTC at UW allowed for comparison of results with parallel OC screening. The diagnostic yield and complication rates of each method were compared in a 2007 publication involving over 6000 screening individuals who either underwent primary CTC screening (n = 3120) or primary OC screening (n = 3163) [52] . The two cohorts were drawn from the same general population and were closely matched in terms of age, gender, and family history. Advanced neoplasia was the primary outcome measure, representing the primary target of colorectal cancer prevention and screening. Although only 8% of individuals in the CTC arm underwent OC (compared with a 100% OC utilization rate in the OC arm), the same number of advanced neoplasms were detected and removed (123 for CTC, 121 for OC), with more cancers (14 vs. 4) . The test-positive rates for both CTC and OC were similar at both the 6-mm (12.9% and 13.4%) and 10-mm (5.3% and 4.2%) thresholds, respectively. Despite equivalent detection and removal of advanced neoplasia, only 561 total polyps were removed in the CTC arm, compared with 2434 polypectomies in the OC arm. There were no significant complications in the CTC cohort but seven colonic perforations (0.2%) in the primary OC arm [52] . Thus, the CTC arm with selective use of OC was able to identify the same number of advanced adenomas with far fewer polypectomies performed and fewer complications compared with the primary OC arm, demonstrating its value as a primary screening examination.
Subsequent publications from the UW CTC screening program have looked at long-term follow-up of discordant cases when CTC findings are not seen at initial OC [53] , results of 5-10 year CTC re-screening and the practice of not reporting isolated diminutive lesions [54] , experience with detecting serrated polyps at CTC [55] , and the positive impact of insurance coverage for CTC upon overall CRC-screening rates [56] , among others. The UW and NNMC programs teamed up on reporting the natural history of small 6-9 mm polyps at surveillance CTC [57] .
The last decade has witnessed a number of additional milestones for CTC screening. Although the USPSTF levied an ''I'' grade for CTC screening in its 2008 CRC guidelines revision, which led to the aforementioned noncoverage status by CMS, the recently updated 2016 guidelines included CTC in its ''A'' grade recommendation for screening adults 50-75 years of age [58, 59] . In 2010, the AMA issued a Category I CPT code for CTC screening. That same year, President Obama was screened by CTC at Bethesda, whereas in the previous administration, President Bush was screened by OC. In 2013, a FDA joint panel of the Medical Devices Advisory Committee supported the use of CTC for screening. All of the members of the joint panels agreed that, given the risks and benefits identified, CTC should be an option for CRC screening of asymptomatic patients.
[https://www.fda.gov/NewsEvents/MeetingsConferences Workshops/ucm367975.htm. Accessed on September 15, 2017] There has been consistent interest and support for the use of CTC for colorectal cancer screening from both the House of Representatives and the Senate since 2010 with the introduction of legislation each year requesting amendment of title XVIII of the Social Security Act to provide Medicare coverage for screening CTC as a colorectal cancer screening test. Although there has been no action on these bills, legislative efforts continue. [https:// www.congress.gov/bill/111th-congress/house-bill/5461. Accessed on September 15, 2017] At the state level, there is variability in the approach to reimbursement for screening CTC. Some states such as Delaware and Connecticut mandate coverage of colorectal cancer screening by all private payers in accordance with American Cancer Society guidelines. Others follow recommendations established by the American College of Gastroenterology which do not include CTC for screening. Importantly, the five largest national insurance companies (Aetna, Anthem, Cigna, UniCare, and United) have moved toward broad coverage for screening CTC.
Conclusion
At the time of this writing, CMS has still not reopened the NCD for CTC screening. However, the authors see no legitimate reason why CTC should not be a covered screening test for Medicare beneficiaries-or for any other health insurance plan, for that matter. CTC has proven itself repeatedly to be clinically efficacious, highly cost effective, have an excellent safety profile, and have a strong patient preference. In short, CTC is better, faster, safer, and cheaper than OC-and also provides the critical preventive component largely missing in the emerging stool-or blood-based CRC-screening tests. A substantive change in how CRC screening is reimbursed, such as bundled payments, could immediately turn things around for CTC. To date, much like the colon itself, the path for CTC has been a truly long and winding road-but many more exciting chapters are yet to be written.
